Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16404629 | 0.85 | CES2 (0.46) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL107636 | 0.85 | CSNK2A1 (0.52) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL28471721 | 0.85 | CES2 (0.48) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL7787350 | 0.83 | CES2 (0.47) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL108796 | 0.81 | SMN1; SMN2 (0.47) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL20184142 | 0.81 | MAPT (0.47) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL26020411 | 0.80 | CES2 (0.49) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL24177167 | 0.79 | CES2 (0.47) | CES2MAPTGPR52ALDH1A1PARP1 | |
| SCHEMBL29789763 | 0.79 | CES2 (0.47) | CES2PARP1DGAT1KMT2AMAPK10 | |
| SCHEMBL29789661 | 0.79 | CES2 (0.47) | CES2MAPTGPR52ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888519-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2007054139-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
| WO-2013144737-A2 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2013-10-03 | — | — | WO | disclosed |
| EP-1775289-B1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-7803826-B2 | Imidazolidine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7803826-B2 | Imidazolidine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1775289-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | CES2 4136/4885SMN1; SMN2 196/4885TP53 24/4885 |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | CES2 1332/4885SMN1; SMN2 696/4885TP53 4535/4885 |
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CYP3A4, CYP4B1, OPRD1 | CES2 405/4885SMN1; SMN2 3704/4885TP53 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.